These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3178380)

  • 21. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease.
    Lancet; 1981 Jan; 1(8210):44-5. PubMed ID: 6109080
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pleuropulmonary fibrosis and bromocriptine].
    Vergeret J; Barat M; Taytard A; Bellvert P; Domblides P; Douvier JJ; Fréour P
    Sem Hop; 1984 Mar; 60(11):741-4. PubMed ID: 6324351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism.
    Baas H; Schneider E; Fischer PA; Japp G
    J Neural Transm; 1985; 64(1):45-54. PubMed ID: 4067602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.
    Shiraishi M; Kamo T; Hotta M; Nemoto S; Oshima J; Sugihara H; Yasaki S; Kawakami M; Takahashi Y; Shimojo S
    J Neural Transm (Vienna); 2004 Jun; 111(6):725-32. PubMed ID: 15168219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
    Pfeiffer RF; Wilken K; Glaeske C
    Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
    Haro-Estarriol M; Sabater-Talaverano G; Rodríguez-Jerez F; Obrador-Lagares A; Genís-Batlle D; Sendra-Salillas S
    Arch Bronconeumol; 2009 Feb; 45(2):100-2. PubMed ID: 19232272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
    Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M
    Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pleural effusion and constrictive pericarditis secondary to bromocriptine treatment].
    Saura J; Aguilar M; Alió J
    Neurologia; 1991 Nov; 6(9):331-3. PubMed ID: 1809340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
    Villavicencio C; Ramírez-Sarmiento A; Gayete A; Grau S; Orozco-Levi M
    Arch Bronconeumol; 2007 Sep; 43(9):519-22. PubMed ID: 17919420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic constrictive pericarditis induced by long-term bromocriptine therapy: report of two cases.
    Champagne S; Coste E; Peyrière H; Nigond J; Mania E; Pons M; Hillaire-Buys D; Balmes P; Blayac JP; Davy JM
    Ann Pharmacother; 1999 Oct; 33(10):1050-4. PubMed ID: 10534217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
    Townsend M; MacIver DH
    Heart; 2004 Aug; 90(8):e47. PubMed ID: 15253989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Severe pleuropericarditis induced by long-term bromocriptin therapy, report of a case and review of the literature].
    Ciubotaru V; Poinsignon Y; Brunet-Bourgin F; Mestassi M; Rosenbaum D
    Rev Med Interne; 2004 Apr; 25(4):310-4. PubMed ID: 15050800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
    Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
    Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease.
    Serby M; Angrist B; Lieberman A
    Am J Psychiatry; 1978 Oct; 135(10):1227-9. PubMed ID: 29497
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pleural effusion induced by bromocriptine].
    Diot E; Diot P; Le Rolland A; Jonville AP; Lasfargues G; Lemarie E; Lavandier M; Guilmot JL
    Rev Mal Respir; 1990; 7(2):175-7. PubMed ID: 2320790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rounded atelectasis and respiratory compromise secondary to pergolide use.
    Bloom CI; Wilson GE
    Respirology; 2009 Aug; 14(6):906-7. PubMed ID: 19659834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA; Burns RS; Calne DB
    Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.